drug_type
RELEVANT_DRUG
intervention_type
radiopharmaceutical (radioimmunotherapy)
drug_description
Lutetium-177–DOTA–girentuximab, a CAIX-targeted radioimmunotherapy delivering beta radiation to CAIX-positive tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Girentuximab
drug_category
RADIOIMMUNOCONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
177Lu-TLX250 (Lutetium-177–DOTA–girentuximab) is a CAIX-targeted monoclonal antibody radioconjugate. Girentuximab binds CAIX on tumor cells and delivers the beta-emitting radionuclide 177Lu, producing localized radiation (including cross-fire) that induces DNA double-strand breaks and tumor cell death while sparing CAIX-negative tissues.
drug_name
177Lu-TLX250
nct_id_drug_ref
NCT05868174